Novartis Sandoz Likely To Set Up Base In Chongqing
This article was originally published in PharmAsia News
Sandoz China's CEO recently visited Chongqing to check out its business environment. City officials gave details of Chongqing's favorable investment climate, highlighting its pharmaceutical industry infrastructure. Some firms already set up there include Chongqing Yaoyou Pharmaceuticals and Chongqing Southwest Synthetic Pharmaceutical. The city is actively attracting top global 500 companies to build up an industrial manufacturing base, thus the collaboration prospects with Sandoz look promising. Sandoz has expressed optimism in Chongqing's development potential and hopes to work with drug enterprises there to boost the expansion of the local pharmaceutical industry for a win-win relationship. (Click here for more - Chinese Language)
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.